Hosta

by | Mar 16, 2018 | Hosta

How Can We Help?
You are here:
< Back

FV-100, also known as Cf1743, is an orally available nucleoside analogue drug[1] with antiviral activity.[2] It may be effective against shingles.[3]

It was discovered in 1999 in the laboratories of Prof Chris McGuigan, Welsh School of Pharmacy and Prof. Jan Balzarini, Rega Institute, Leuven, Belgium.[4]

Clinical trials

FV-100 was tested against valaciclovir in a phase II trial in patients with herpes zoster. The trial was sponsored by Bristol-Myers Squibb.[5] The drug is currently being developed by ContraVir Pharmaceuticals, Inc., Edison, New Jersey.[6] It has reached Phase III clinical trials.[7]

References

  1. ^ Inhibitex Completes Phase I Clinical Trials For FV-100 And Selects Lead HCV Compounds For Advanced Preclinical Studies, 2009
  2. ^ McGuigan, Christopher; Balzarini, Jan (2009). "FV100 as a new approach for the possible treatment of varicella-zoster virus infection". Journal of Antimicrobial Chemotherapy. 64 (4): 671–673. doi:10.1093/jac/dkp294. PMID 19679595.
  3. ^ Tyring SK, Lee P, Hill GT Jr, Silverfield JC, Moore AY, Matkovits T, Sullivan-Bolyai J. FV-100 versus valacyclovir for the prevention of post-herpetic neuralgia and the treatment of acute herpes zoster-associated pain: A randomized-controlled trial. J Med Virol. 2017 Jul;89(7):1255-1264. doi:10.1002/jmv.24750 PMID 27943311
  4. ^ Cardiff School of Pharmacy; Pharmaceutical Sciences, Step forward for shingles drug - FV100. Shows structure of FV100.
  5. ^ A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster, 23 September 2015
  6. ^ ContraVir Pharmaceuticals: FDA Meeting About Antiviral Drug Trial., January 2015
  7. ^ De Clercq E, Li G. Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev. 2016 Jul;29(3):695-747. doi:10.1128/CMR.00102-15 PMID 27281742


Categories
Table of Contents